Abstract
ObjectivesTo investigate the efficacy and safety of switching from infliximab reference product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing spondylitis (AS).MethodsThis open-label extension study recruited...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have